OBJECTIVE: The aim of this study is to evaluate the efficacy of carboplatin-paclitaxel (TC) as an initial treatment in patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IVb cervical cancer. METHODS: We retrospectively reviewed seven patients with stage IVb cervical cancer who have been primarily treated with TC. The activity and the toxicity were evaluated. Response rate was the main endpoint. RESULTS: Overall, the treatment of TC was well tolerated. The overall response rate was 71.4% (2 complete response, 3 partial response). Although grade 3-4 hematologic toxicities were observed in 3 out of 7 patients (42.8%), no patients experienced grade 3-4 non-hematologic toxicities. When we combined our present results with the previous reports, the overall response rate of TC is 63.6%. CONCLUSION: TC is active and well tolerated in patients FIGO stage IVb cervical cancer. This combination may be considered as an initial treatment regimen in this patient population.
OBJECTIVE: The aim of this study is to evaluate the efficacy of carboplatin-paclitaxel (TC) as an initial treatment in patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IVb cervical cancer. METHODS: We retrospectively reviewed seven patients with stage IVb cervical cancer who have been primarily treated with TC. The activity and the toxicity were evaluated. Response rate was the main endpoint. RESULTS: Overall, the treatment of TC was well tolerated. The overall response rate was 71.4% (2 complete response, 3 partial response). Although grade 3-4 hematologic toxicities were observed in 3 out of 7 patients (42.8%), no patients experienced grade 3-4 non-hematologic toxicities. When we combined our present results with the previous reports, the overall response rate of TC is 63.6%. CONCLUSION:TC is active and well tolerated in patients FIGO stage IVb cervical cancer. This combination may be considered as an initial treatment regimen in this patient population.
Authors: W P McGuire; J Arseneau; J A Blessing; P J DiSaia; K D Hatch; F T Given; N N Teng; W T Creasman Journal: J Clin Oncol Date: 1989-10 Impact factor: 44.544
Authors: Angeles Alvarez Secord; Laura J Havrilesky; Michael E Carney; John T Soper; Daniel L Clarke-Pearson; Gustavo C Rodriguez; Andrew Berchuck Journal: Int J Clin Oncol Date: 2007-02-25 Impact factor: 3.402
Authors: Kathleen N Moore; Thomas J Herzog; Sharyn Lewin; Robert L Giuntoli; Deborah K Armstrong; Rodney P Rocconi; Whitney A Spannuth; Michael A Gold Journal: Gynecol Oncol Date: 2007-02-14 Impact factor: 5.482
Authors: Harry J Long; Brian N Bundy; Edward C Grendys; Jo Ann Benda; D Scott McMeekin; Joel Sorosky; David S Miller; Lynne A Eaton; James V Fiorica Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544
Authors: David H Moore; John A Blessing; Richard P McQuellon; Howard T Thaler; David Cella; Jo Benda; David S Miller; George Olt; Stephanie King; John F Boggess; Thomas F Rocereto Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: David H Moore; Chunqiao Tian; Bradley J Monk; Harry J Long; George A Omura; Jeffrey D Bloss Journal: Gynecol Oncol Date: 2009-10-22 Impact factor: 5.482
Authors: Jing Jing Liu; Jung Yoon Ho; Hye Won Lee; Min Wha Baik; Oyoung Kim; Youn Jin Choi; Soo Young Hur Journal: Int J Mol Sci Date: 2019-07-10 Impact factor: 5.923
Authors: M McCormack; L Kadalayil; A Hackshaw; M A Hall-Craggs; R P Symonds; V Warwick; H Simonds; I Fernando; M Hammond; L James; A Feeney; J A Ledermann Journal: Br J Cancer Date: 2013-05-21 Impact factor: 7.640